InvestSMART

Cambium Bio Limited (ASX:CMB)

ALERT: Price-sensitive ASX Announcement for CMB
Current share price for CMB : $0.360 -0.07 (-16.28%)+
Announcement
Release
30 Jul 2026 8:51AM
Price at Release
$0.430
Full Release
download
Summary
Cambium Bio Limited reported a net operating cash outflow of A$0.799 million for the quarter ending 30 June 2026, with closing cash of A$1.104 million. Key expenditures included A$0.654 million on research and development, largely for clinical trial preparation and regulatory activities. The company received A$0.150 million from customer receipts and announced a funding strategy involving a A$1.008 million placement and expected research and development tax incentives. The pivotal Phase 3 CAMOMILE-2 study design was completed, aiming to strengthen their financial position for future trials. The company has less than two quarters of funding available, highlighting the critical need for additional capital to support ongoing operations and the upcoming clinical trials.
Key Points
  • Net operating cash outflow of A$0.799 million for the quarter.
  • Receipts from customers amounted to A$0.150 million.
  • Research and development expenses were A$0.654 million.
  • Closing cash balance was A$1.104 million as of 30 June 2026.
  • The company expects a research and development tax incentive rebate for FY2026.
  • A placement to raise A$1.008 million was announced post quarter end.
  • The pivotal Phase 3 study design, CAMOMILE-2, was finalised.
  • No investing cash flows were recorded during the quarter.
  • A net financing cash outflow of A$0.261 million was due to loan repayments.
  • Estimated quarters of funding available are less than two.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.